Key facts
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Oct 2025.
- Notable investors include Flagship Pioneering, Altitude Life Science Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Expedition Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Expedition Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Expedition Medicines
Developer of a drug discovery platform designed to generate small molecule drugs for previously inaccessible disease targets. The company's platform features continuous chemoproteomics data generation, quantum chemistry-powered artificial intelligence for mapping covalent bond formation at atomic precision, and generative molecular design, enabling pharmaceutical researchers to access undruggable protein surfaces and advance therapies across oncology, immunology, and other diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 36
- Website
- expeditionmedicines.com/
- Ownership
- Privately Held (backing)
Expedition Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Expedition Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Expedition Medicines in its N-PORT filings yet. We sweep new filings monthly.